Aldeyra Therapeutics

United States
Prairie City, Iowa, United States
+1 781 761 4904 ★

Company profile

Aldeyra Therapeutics company profile

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Business identity

Contact email
[email protected]
Phone number
+1 781 761 4904
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2004-01-01

Headquarters

Headquarters
Prairie City, Iowa, United States
Postal code
01803
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
5
Total equity funding
$227.4M
Last funding
Post Ipo Equity / $125M / 2021-04-28
Last equity funding
Post Ipo Equity / $125M
Investors
1
Lead investors
1
Founders
2
Articles
266
Exited on
2014-05-05

Founders and investors

Founders

John E. DowlingThomas A. Jordan

Lead investors

Hercules Capital

Investors

Hercules Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.